Morepen Laboratories Ltd (MOREPENLAB) — shareholding pattern, promoter holding, financials and share price
About Morepen Laboratories Ltd (MOREPENLAB)
Morepen Laboratories Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as MOREPENLAB and on the BSE under scrip code 500288. Its ISIN is INE083A01026.
Morepen Laboratories Ltd is engaged in the business of manufacturing, producing, developing and marketing a wide range of Active Pharmaceutical Ingredients (APIs), branded and generic formulations and also the Home Health products. [1]
Morepen Laboratories is an India-based integrated pharmaceutical and medical-device company producing APIs, formulations and point-of-care medical devices with a product mix split roughly 62% pharma (API+Rx) and 38% medical devices, and manufacturing sites including a USFDA-approved facility and a hi-tech pharma complex in Himachal Pradesh.
Financial momentum in Q3 FY26 shows consolidated gross revenue of Rs. 488 crores and standalone gross revenue of Rs. 462 crores with strong sequential improvement: consolidated PAT rose 83% year-on-quarter (Q2 to Q3) and standalone PAT increased 77%, reflecting operating leverage and non-recurring income components in the quarter.
Listed peers in Pharmaceuticals: SMS Pharmaceuticals Ltd, Novartis India Ltd, Aarti Drugs Ltd, Panacea Biotec Ltd, Dishman Carbogen Amcis Ltd, Hikal Ltd.
Valuation & Returns
10 Jul 2026At ₹61.2 a share on 10 Jul 2026, Morepen Laboratories Ltd (MOREPENLAB) was valued at a price-to-earnings ratio of 35.06x against an industry P/E of 36.41x and a price-to-book of 2.9x on a book value of ₹21.1 per share as of Mar 2025. Solomo computes return on equity of 8.27% and return on capital employed of 10.81% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 35.06x
- Industry P/E
- 36.41x
- P/B
- 2.9x
- EPS (TTM)
- ₹1.75
- Book value / share
- ₹21.1
- ROE
- 8.27%
- ROCE
- 10.81%
- ROA
- 5.38%
- Debt / equity
- 0.09x
- Dividend yield
- 0.33%
- EBITDA margin
- 9.57%
- 52-week range
- ₹33.44 – ₹65.07
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Morepen Laboratories Ltd (MOREPENLAB) reported revenue of ₹1,806 crore, net profit of ₹96 crore and earnings per share of ₹1.73. That compares with revenue of ₹1,812 crore and net profit of ₹118 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹485 crore and net profit ₹16 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 1,547 | 1,418 | 1,690 | 1,812 | 1,806 |
| Net profit (₹ cr) | 102 | 39 | 97 | 118 | 96 |
| EPS (₹) | 2.13 | 0.76 | 1.88 | 2.15 | 1.73 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 14.70% | 14.44% | 2.36% | 7.17% |
| Profit growth | 22.99% | 25.73% | 0.17% | 22.15% |
| Stock price CAGR | 10% | -2% | 26% | -4% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 35.65% of Morepen Laboratories Ltd (MOREPENLAB) (unchanged from the previous quarter), foreign institutional investors (FII) hold 1.46% and domestic institutional investors (DII) hold 1.28%. Market capitalisation was ₹3,353 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: PINFOLD OVERSEAS LIMITED 7.03%, Unclaimed or Suspense or Escrow Account 1.02%, MOREPEN LABORATORIES LIMITED 1.02%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 35.65% | - | 1.46% | 1.28% | 64.35% |
| Mar 2026 | 35.65% | - | 1.58% | 1.25% | 64.35% |
| Dec 2025 | 35.65% | - | 1.62% | 1.25% | 64.35% |
| Sep 2025 | 35.65% | - | 1.62% | 1.5% | 64.35% |
| Jun 2025 | 35.65% | - | 1.72% | 1.51% | 64.35% |
| Mar 2025 | 35.65% | - | 1.94% | 1.67% | 64.35% |
| Dec 2024 | 35.65% | - | 2.22% | 1.64% | 64.35% |
| Sep 2024 | 35.65% | - | 2.08% | 1.7% | 64.35% |